Monday, April 1, 2013

Indian Supreme Court Denies New Patent For Cancer Treatment.

The AP (4/1, George) reports, "India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent a new version of" cancer treatment Glivec (imatinib mesylate), "in a landmark decision that healthcare activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines." The case "has global implications since India's $26 billion generic drug industry supplies much of the cheap medicine used in the developing world." India's patent office didn't issue a fresh patent for the medicine "because it was not a new medicine but an amended version of its earlier product," citing "a legal provision in India's 2005 patent law aimed at preventing companies from getting fresh patents for making only minor changes," which is called "evergreening."

        The New York Times (4/1, Harris, Subscription Publication) reports, "The court's ruling confirmed that India's criteria for the granting of such patents remain far higher than those in the United States, where patents are so easy to win that one was given in 1999 for a peanut butter-and-jelly sandwich." The Times adds, "In recent decades, the United States has become increasingly insistent that countries wishing to do business there adopt far more stringent patent protection rules, with the result that poorer patients often lose access to cheap generic copies of medicines when their governments undertake trade agreements with the United States."

        Bloomberg News (4/1, Von Schaper, Patnaik) reports the decision was "watched by non-profit groups seeking to expand access to medicines and drugmakers concerned about India's position on intellectual property." This "may add to concern among Western pharmaceutical companies that India is allowing domestic generic-drug makers to profit from products that deserve patent protection." India also "angered pharmaceutical companies by allowing generic-drug makers to produce copies of patent-protected medicines to ensure they're available in the country at affordable prices."
        The BBC News (4/1) reports a month of Glivec costs about $2,600, compared to $175 for the same amount of its generic equivalent in India. Reuters (4/1, Mohanty, Kulkarni) also covers this story.
DIA Daily. This daily enewsletter features summaries of breaking news and information about the pharmaceutical, biotechnology, and medical device fields from thousands of global news sources. This easy-to-read enewsletter is delivered to your inbox every business morning.
Subscribe to the DIA Daily.
View archives.
iPhone and iPad Apps available! Download "BulletinHC."DIA Daily is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare. The presence of content or advertising does not endorse, nor imply endorsement of, any products or services by the Drug Information Association. Neither BulletinHealthcare nor the Drug Information Association is liable for the use of or reliance on any information contained in this briefing.

If you would like more information about, or have a question pertaining to, DIA Membership and its benefits, please email here to check your membership status.

Drug Information Association | 800 Enterprise Road, Suite 200 | Horsham, PA 19044
Copyright © 2012 by BulletinHealthcare| 11190 Sunrise Valley Drive, Suite 130 | Reston, VA 20191

6th Regulatory Conference | NEW DATE! May 23-24, 2013 | Ahmedabad, India
Book Now to Enjoy Insightful Sessions in May
Dear Colleagues,
Due to unavoidable circumstances we will be postponing the 6th Regulatory Conference in India. The conference will now be held on Thursday 23rd and Friday 24th May at the Courtyard Marriott in Ahmedabad, Gujarat.
It is DIA’s constant endeavor to bring to you world class programs with renowned speakers. We hope you can join us at the conference in May.
Seats are still available for the event. Please take a look at the conference program to find the sessions that interest you and register today.
Best regards,
DIA India
Conference on Technological Advances in Meeting Regulatory Challenges
Email Preferences | My DIA | Forward to a Friend | Facebook LinkedIn Twitter YouTube Flickr

No comments:

Post a Comment